J&J adds first new indication for Caplyta since takeover

Johnson & Johnson has clinched an FDA approval for Caplyta in depression, satisfying a major driver for its $14.6bn takeover of ICT this year.

J&J agrees $14.6bn takeover of CNS biotech Intra-Cellular

Johnson & Johnson has agreed to take over Intra-Cellular Therapies and its potential depression blockbuster Caplyta in a deal worth up to $14.6bn.

Intra-Cellular sets up $500m offer on Caplyta depression win

Shares in Intra-Cellular Therapies rose sharply after it reported that its only product Caplyta was effective for a new indication, major depressive disorder (MDD), in a p

Intra-Cellular ends year with OK for schizophrenia drug luma...